Laboratorios ERN’s Presence at the Meeting with the President of the Spanish Government

David Solanes López, General Director of Laboratorios ERN, met on February 12, 2025, with the President of the Government of Spain, Pedro Sánchez, along with other executives from the national and multinational pharmaceutical industry, Farmaindustria, EFPIA, and the Minister of Health, Mónica García, the Minister of Industry, Jordi Hereu, and other members of the Government.

Following the first meeting held in December 2022, which marked the launch of the work plan and the publication of the Pharmaceutical Industry Strategy, this second meeting highlighted the importance of pharmaceutical companies’ plans, emphasizing the sector’s commitment to Spain and announcing that between 2023 and 2025, pharmaceutical investment will exceed €8 billion. This investment reaffirms the strategic role of the industry in innovation, sustainability, and the creation of high-quality jobs.

Additionally, David Solanes intervened, requesting that the Administration consider the sustainability of national pharmaceutical SMEs when introducing legislative changes. As an example, he mentioned the impact that the Urban Wastewater Treatment Directive could have on the future of pharmaceutical SMEs and their employees, as it would be entirely unfeasible if implemented under the current terms.

In this context, it was emphasized that the pharmaceutical industry is a key asset and a fundamental sector for strengthening public-private collaboration and consolidating Spain as a leader in biomedical research and production. Furthermore, the implementation of legislative reforms, such as the Royal Decree on Health Technology Assessment and the Royal Decree on Pricing and Financing, will help facilitate access to new medicines and promote a stable and predictable regulatory environment.

Looking ahead, the pharmaceutical industry’s commitment to innovation and sustainability will continue to be essential in ensuring access to effective treatments and improving the population’s quality of life. At Laboratorios ERN, we will continue to invest in the development of innovative solutions, aligning with national and European strategies to strengthen the pharmaceutical ecosystem. The combination of investment, collaboration, and scientific advancements will enable Spain to further consolidate its position as a benchmark in biomedical research, fostering sustainable growth that benefits society as a whole.